JOP20170104A1 - مشتقات فنيل تريازول مستبدلة بأميد واستخدامها - Google Patents

مشتقات فنيل تريازول مستبدلة بأميد واستخدامها

Info

Publication number
JOP20170104A1
JOP20170104A1 JOJO/P/2017/0104A JOP20170104A JOP20170104A1 JO P20170104 A1 JOP20170104 A1 JO P20170104A1 JO P20170104 A JOP20170104 A JO P20170104A JO P20170104 A1 JOP20170104 A1 JO P20170104A1
Authority
JO
Jordan
Prior art keywords
amid
compounds
phenyltriazole derivatives
substituted
substituted phenyltriazole
Prior art date
Application number
JOJO/P/2017/0104A
Other languages
English (en)
Inventor
Kolkhof Peter
Collin Marie-Pierre
Neubauer Thomas
Furstner Chantal
Pook Elisabeth
Beat Wittwer Matthias
Lustig Klemens
Buchmuller Anja
Tinel Hanna
Drobner Karoline
Mondritzki Thomas
Schirmer Heiko
Kretschmer Axel
Schmeck Carsten
Wasnaire Pierre
Cernecka Hana
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JOP20170104A1 publication Critical patent/JOP20170104A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 5-(carboxamide)-1-phenyl-1,2,4-triazole جديدة، وبعمليات لتحضير هذه المركبات، وبتراكيب صيدلية تحتوي على هذه المركبات، وباستخدام هذه المركبات أو التركيبات لمعالجة و/أو الوقاية من الأمراض، تحديدا لمعالجة و/أو الوقاية من الأمراض الكلوية وأمراض القلب والأوعية الدموية.
JOJO/P/2017/0104A 2016-05-03 2017-05-02 مشتقات فنيل تريازول مستبدلة بأميد واستخدامها JOP20170104A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16168163 2016-05-03

Publications (1)

Publication Number Publication Date
JOP20170104A1 true JOP20170104A1 (ar) 2017-11-03

Family

ID=55910849

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2017/0104A JOP20170104A1 (ar) 2016-05-03 2017-05-02 مشتقات فنيل تريازول مستبدلة بأميد واستخدامها

Country Status (7)

Country Link
US (1) US10815205B2 (ar)
EP (1) EP3452470B1 (ar)
AR (2) AR108265A1 (ar)
JO (1) JOP20170104A1 (ar)
TW (1) TW201806943A (ar)
UY (1) UY37221A (ar)
WO (1) WO2017191107A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
US11298367B2 (en) 2017-10-24 2022-04-12 Bayer Aktiengesellschaft Prodrugs of substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081302A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
US20230340101A1 (en) * 2019-12-23 2023-10-26 Sanofi Biotechnology Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
KR102836167B1 (ko) 2020-07-14 2025-07-21 삼성전자주식회사 반도체 소자
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US20170313665A1 (en) 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
AR108263A1 (es) 2018-08-01
EP3452470A1 (en) 2019-03-13
US10815205B2 (en) 2020-10-27
WO2017191107A1 (en) 2017-11-09
AR108265A1 (es) 2018-08-01
EP3452470B1 (en) 2020-03-18
TW201806943A (zh) 2018-03-01
UY37221A (es) 2017-11-30
US20190161454A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12018500284B1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
EA201891609A1 (ru) Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2016004114A (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA202190281A1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
PH12017501668A1 (en) Bace1 inhibitors
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
WO2019028309A1 (en) AZAINDOLES AND THEIR METHODS OF USE
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена
EA201990074A1 (ru) Гетероциклические соединения как иммуномодуляторы
HK1209575A2 (en) Isoquinolinone derivatives as nk3 antagonists